Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frances-Catherine Quevenco

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Neuroimage|March 26, 2013
EEG alpha activity is associated with individual differences in post-break improvementJulian Lim, Frances-Catherine Quevenco, Kenneth Kwok
Clinical Chemistry and Laboratory Medicine|October 25, 2022
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's diseaseKaj Blennow, Erik Stomrud, Henrik Zetterberg, et al.
Journal of Alzheimer'S Disease : JAD|March 20, 2025
Diagnostic journey and management of patients with mild cognitive impairment and Alzheimer's disease dementia: A multinational, real-world surveySimona Z Vasileva-Metodiev, Drew Spargo, Eric G Klein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 11, 2023
The potential clinical value of plasma biomarkers in Alzheimer's diseaseKaj Blennow, Douglas Galasko, Robert Perneczky, et al.
JAMA Network Open|September 13, 2021
Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease: A Systematic Review and Meta-analysisJulie Martinkova, Frances-Catherine Quevenco, Helene Karcher, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 2, 2022
Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratiosFemke H Bouwman, Giovanni B Frisoni, Sterling C Johnson, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 15, 2026
Interchangeability of CSF and PET to identify Alzheimer's disease pathologySamantha C Burnham, Anupa K Arora, Leonardo Iaccarino, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 5, 2025
How can Alzheimer's disease blood-based biomarkers reach clinical practice?Robert Perneczky, Frances-Catherine Quevenco, James Hendrix, et al.
Brain Communications|December 26, 2024
The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's diseaseRaffaele Cacciaglia, Mahnaz Shekari, Gemma Salvadó, et al.
Alzheimer'S Research & Therapy|December 20, 2024
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer's prevention research cohortLidia Canals-Gispert, Alba Cañas-Martínez, Gema Huesa, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Neuroimage|March 26, 2013
EEG alpha activity is associated with individual differences in post-break improvementJulian Lim, Frances-Catherine Quevenco, Kenneth Kwok
Clinical Chemistry and Laboratory Medicine|October 25, 2022
Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's diseaseKaj Blennow, Erik Stomrud, Henrik Zetterberg, et al.
Journal of Alzheimer'S Disease : JAD|March 20, 2025
Diagnostic journey and management of patients with mild cognitive impairment and Alzheimer's disease dementia: A multinational, real-world surveySimona Z Vasileva-Metodiev, Drew Spargo, Eric G Klein, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 11, 2023
The potential clinical value of plasma biomarkers in Alzheimer's diseaseKaj Blennow, Douglas Galasko, Robert Perneczky, et al.
JAMA Network Open|September 13, 2021
Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease: A Systematic Review and Meta-analysisJulie Martinkova, Frances-Catherine Quevenco, Helene Karcher, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 2, 2022
Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratiosFemke H Bouwman, Giovanni B Frisoni, Sterling C Johnson, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 15, 2026
Interchangeability of CSF and PET to identify Alzheimer's disease pathologySamantha C Burnham, Anupa K Arora, Leonardo Iaccarino, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 5, 2025
How can Alzheimer's disease blood-based biomarkers reach clinical practice?Robert Perneczky, Frances-Catherine Quevenco, James Hendrix, et al.
Brain Communications|December 26, 2024
The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's diseaseRaffaele Cacciaglia, Mahnaz Shekari, Gemma Salvadó, et al.
Alzheimer'S Research & Therapy|December 20, 2024
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer's prevention research cohortLidia Canals-Gispert, Alba Cañas-Martínez, Gema Huesa, et al.
Pageof 2